Certified by Founder
Lodge
PAQ Therapeutics
start up
United States
- Burlington, MA
- 08/05/2025
- Series B
- $39,000,000
PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body’s most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ’s research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.
- Industry Biotechnology Research
- Website https://www.paqtx.com/
- LinkedIn https://www.linkedin.com/company/paq-therapeutics/
SPARK Microsystems | $12,364,525 | (Mar 24, 2026)
Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Hamilton AI | $7,500,000 | (Mar 24, 2026)
Flourish Care | $5,700,000 | (Mar 24, 2026)
Interloom | $16,500,000 | (Mar 24, 2026)
eternal.ag | $9,271,160 | (Mar 24, 2026)
EGIDE | $9,266,200 | (Mar 24, 2026)
Cleavr | $1,158,600 | (Mar 24, 2026)
JAAQ | $17,416,100 | (Mar 24, 2026)
CisLunar Industries | $2,600,000 | (Mar 24, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)